Treatment with SB431542 causes a significant downregulation of anterior positional markers including PAX6, OTX1, OTX2 and the midbrain marker EN2 by transcriptional analysis and significantly reduced expression of PAX6 and OTX2 by immunohistochemistry compared to control conditions
SB431542 accelerates reduction of pluripotency DCVC (E-isomer) biological activity markers OCT4 and NANOG to...